 Mersana Therapeutics Inc NASDAQ: MRSN stock is moving lower during the market trading session. Investors are reacting to interim data from the ovarian cancer Phase 1 trial evaluating Upifitamab Rilsodotin UpRi, previously XMT-1536. 